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The U.S. Consumer Product Safety Commission (CPSC) is an independant regulatory agency that
was created in 1973. The CPSC has jurisdiction over more the 15,000 types of consumer
products used in and around the home or by children, except items such as food, drugs,
cosmetics, medical devices, pesticides, certain radioactive materials, products that emit radiation
(e.g., microwave ovens), and automobiles. The CPSC has investigated many low-level exposures
from consumer products, including formaldehyde emissions from urea-formaldehyde foam
insulation and pressed wood products, CO and NO2 emmisions from combustion appliances, and
dioxin in paper products. Many chemical hazards are addressed under the Federal Hazardous
Substances Act (FHSA), which applies to acute and chronic health effects resulting from high- or
low-level exposures. In 1992 the Commission issued guidelines for assessing chronic hazards
under the FHSA, including carcinogenicity, neurotoxicity, reproductive/developmental toxicity,
exposure, bioavailability, risk assessment, and acceptable risk. The chronic hazard guidelines
describe a series of default assumptions, which are used in the absence of evidence to the
contrary. However, the guidelines are intended to be sufficiently flexible to incorporate the latest
scientific information. The use of alternative procedures is permissible, on a case-by-case basis,
provided that the procedures used are scientifically defensible and supported by appropriate
data. The application of the chronic hazard guidelines in assessing the risks from low-level
exposures is discussed. Environ Health Perspect 106(Suppl 1):387-390 (1998).
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Introduction
The U.S. Consumer Product Safety materials, products that emit radiation
Commission (CPSC) is an independent reg- (e.g., microwave ovens), and automobiles
ulatory agency that was created in 1973. (1). Some low-level exposures that the
The CPSC has jurisdiction over more than CPSC has investigated include: asbestos in
15,000 types ofconsumer products used in plaster products (2); formaldehyde emis-
and around the home or by children, except sions from urea-formaldehyde foam insula-
items such as food, drugs, cosmetics, medical tion (3) and pressed wood products (4);
devices, pesticides, certain radioactive tris(2,3-dibromopropyl) phosphate flame
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retardant in children's sleepwear (5);
nitrosamines in infant pacifiers (6,7); CO
and NO2 emissions from combustion
appliances (8,9); polycyclic aromatic hydro-
carbon emissions from wood stoves (10);
methylene chloride in paint removers and
other products (11-14); volatile organic
compound emissions from carpets (15) and
carpet cushions (16); and dioxin in paper
products (17).
The statutes administered by the CPSC
that address chemical or toxic hazards
include the Consumer Product Safety Act,
Federal Hazardous Substances Act (FHSA),
and Poison Prevention Packaging Act. The
CPSC has a range of risk-management
options available, induding information and
education, voluntary standards, mandatory
labeling, mandatory performance standards,
recalls, and bans. Many chemical hazards are
addressed under the FHSA, which applies to
acute and chronic health effects resulting
from high- or low-level exposures. Under the
FHSA the least burdensome option that ade-
quately addresses the hazard at issue must be
applied and the expected benefits ofthat
action must bear a reasonable relationship to
the costs (18).
Discussion
Under the FHSA (19), the term hazardous
substance is defined as:
Any substance or mixture ofsubstances
which (i) is toxic, (ii) is corrosive, (iii) is
an irritant, (iv) is a strong sensitizer, (v)
is flammable or combustible, or (vi)
generates pressure though decomposi-
tion, heat, or other means, ifsuch a sub-
stance may cause substantial personal
injury or substantial illness during or as
a proximate result of any customary or
reasonably foreseeable handling or use
[emphasis added], including reasonably
foreseeable ingestion by children.
This definition has several implications for
how the CPSC staffperforms risk assess-
ments and which products are regulated.
Regulatory decisions are risk based. Thus,
exposure and bioavailability must be consid-
ered in addition to toxicity (20). This is in
contrast to some ofthe hazard assessment
procedures used by other federal agencies.
For example, under the Occupational Safety
and Health Administration's hazard com-
munication standard (21), a component ofa
mixture that is present at < 1%, or 0.1% for
a carcinogen, may be exempt from labeling
and does not need to be considered in the
hazard determination. On the other hand,
Environmental Health Perspectives * Vol 106, Supplement 1 * February 1998
i
387M.A. BABICH
the presence ofa toxic ingredient would not
automatically trigger a regulation. Under the
hazard communication standard, any car-
cinogen present at >0.1% is considered haz-
ardous regardless of the risk (21). The
properties ofmixtures, rather than individual
ingredients, are generally considered under
the FHSA (19).
The FHSA does not provide for
premarket registration or premarket
approval. This places the burden on manu-
facturers to ensure that products either are
not hazardous or that they are properly
labeled. Also, the FHSA does not include
specific criteria for assessing chronic haz-
ards. In 1992, the Commission issued
guidelines for assessing chronic hazards
under the FHSA, including carcinogenic-
ity, neurotoxicity, reproductive/develop-
mental toxicity, exposure, bioavailability,
risk assessment, and acceptable risk (20).
The methods that the CPSC staff uses to
assess chronic hazards are generally similar
to those ofother federal agencies, with cer-
tain exceptions. The chronic hazard guide-
lines describe a series ofdefault assumptions
that are used in the absence ofevidence to
the contrary. However, the guidelines are
intended to be sufficiently flexible to incor-
porate the latest scientific information.
Deviation from the default procedures is
permissible provided that the procedures
used are scientifically defensible and
supported byappropriate data.
Based on the chronic hazard guidelines,
studies in humans and animals are classi-
fied as providing inadequate, limited, or
sufficient evidence oftoxicity. A substance
or mixture is considered toxic under the
FHSA ifthere is at least limited evidence of
toxicity in humans or sufficient evidence in
animals. For carcinogens the multistage
model is the default procedure for high-to-
low dose extrapolation (Table 1). The
CPSC differs from the U.S. Environmental
Protection Agency (U.S. EPA) (22) and
the U.S. Food and Drug Administration
(U.S. FDA) (23-25) in that the maximum
likelihood estimate (MLE) of risk is used,
provided that the parameter ql is nonzero,
that is, that the MLE is linear at low doses
(20). The surface area correction is used
for animal-to-human extrapolation; surface
area correction is used by the U.S. EPA
(22) but not by the U.S. FDA (25).
Pharmacokinetic modeling may be used to
extrapolate from route to route, high to low
dose, or one exposure regimen to another,
but not for animal-to-human extrapolation
(20). In contrast to the U.S. EPA (22), an
increased incidence ofbenign tumors may
contribute to a finding of sufficient evi-
dence of carcinogenicity in animals if the
benign tumors have the potential to
progress to malignancy (20). Tumors at
independent sites in the same laboratory
animal are considered separate responses
and therefore could support a finding of
sufficient evidence ofcarcinogenicity in ani-
mals (20). These differences are subject to
change, however, as new risk-assessment
methods are adopted (24,26).
The default procedure for assessing
noncancer end points is essentially a safety
factor approach (20). For both cancer and
noncancer end points, an acceptable daily
intake (ADI) is calculated. A substance is
considered hazardous under the FHSA if
the ADI is exceeded during "reasonably
foreseeable handling and use" (19).
Reasons for the differences in risk assess-
ment procedures among federal agencies are
discussed in detail elsewhere (20,23,27).
Some of these differences reflect differ-
ences in the agencies' missions and the
statutes that they administer; others are in
areas ofscientific uncertainty (20,23,27).
Although they use different procedures,
the cancer potency estimates derived by
the CPSC, the U.S. EPA, and the U.S.
FDA generally fall within a 10-fold range
(25). The difference in potency estimates
is mainly attributable to the method of
animal-to-human extrapolation (surface
area or body weight) and choice of risk
metric (MLE or upper bound) (Table 1).
The CPSC works closely with other fed-
eral agencies on issues that cross jurisdic-
tional boundaries, such as methylene
chloride (28), dioxin in paper products
(25), and indoor air quality (29), and has
participated in efforts to harmonize risk-
assessment procedures among federal
agencies (30).
Table 1. Comparison ofquantitative cancer risk assessment procedures used byfederal regulatory agencies.
Agency Dose-response model Dose-response metric Animal-to-human extrapolation
CPSC Multistage Maximum likelihood Surface area
U.S. EPA Multistage Upper bound Surface area
U.S. FDA Gaylor-Kodell Upper bound Bodyweight
OSHA Multistage Maximum likelihood Bodyweight
Sources: CPSC(20), U.S. EPA(22,25), Lorentzen (23), Gaylor(24), and Rhomberg (27).
Three questions posed regarding how
regulatory/public health agencies consider
the biological effects oflow-level exposes
are as follows:
First, does the understanding of the
mechanisms of toxicity affect how the
CPSC assesses risks from exposures to toxic
substances? Knowledge ofthe mechanism
or mode ofaction is incorporated into the
risk-assessment process. The CPSC chronic
hazard guidelines describe a series ofdefault
assumptions to be used in the absence of
information to the contrary. The principal
issue regarding mechanistic information is
not whether it should be incorporated into
the risk-assessment process, but whether
there is sufficient information in a particu-
lar case to deviate from the default assump-
tions (20). For example, a knowledge ofthe
mechanism of action of certain chemicals
that cause tumors in the male rat kidney
suggests that this mechanism is not relevant
in humans (31). This conclusion has been
supported by a considerable body of evi-
dence and there is general agreement in the
scientific community. Therefore, chemicals
acting by this mechanism would be consid-
ered toxic under the FHSA, as they would
under the default assumptions.
Second, does an understanding ofthe
mechanisms by which the body adapts (e.g.,
detoxifies, repairs, etc.) to the effects ofexpo-
sures to toxic substances affect how the
CPSC assesses risks from exposures to toxic
substances? An understanding ofthe mecha-
nisms bywhich the bodydetoxifies or repairs
the effects oftoxic substances can be incor-
porated into the risk-assessment process.
Pharmacokinetic information describes the
manner in which some chemicals are detoxi-
fied aswell as activated. Physiologically based
pharmacokinetic (PBPK) models may be
used to incorporate pharmacokinetic infor-
mation into the risk-assessment process. One
critical issue in developing PBPK models is
the choice ofdose surrogate. The dose surro-
gate might be the concentration ofa toxico-
logically relevant metabolite in the target
tissue. The dose surrogate should be directly
and quantitatively related to the toxic end
point ofinterest. For example, CPSC staff
incorporated a PBPK model into its methyl-
ene chloride cancer risk assessment (12-14).
Methylene chloride is metabolized by two
pathways: a glutathione S-transferase path-
way that is believed to activate methylene
chloride and a mixed-function oxidase path-
way that may be considered to detoxify. In
this case, the dose surrogate was the amount
ofmethylene chloride metabolized by the
glutathione S-transferase pathway in the the
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target tissue. Because the risk in humans was
estimated from animal studies, PBPK mod-
els were developed and validated for humans
aswell as foranimals (12-14).
DNA repair is another type ofrecovery
process that repairs damage induced by car-
cinogens. Thus, some authors have proposed
the use of DNA adducts as measures of
internal dose in risk assessment (32-37). As
with PBPKmodels, thechoice ofdosesurro-
gate is a critical issue. The particular adduct
used as the the dose surrogate should be the
cause ofthe tumors, the tumor response
should be direcdy related to the adduct level,
and the relationship between adduct level
and tumor response should be constant with
dose (36,37). Many chemical carcinogens
induce multiple DNA adducts. For example,
alkylating agents induce a spectrum of
adducts, including 06-alkylguanine and 0
alkylthymine (38-41). 0 -alylguanine is
considered procarcinogenic in the induction
ofnervous system (42) and mammary (43)
tumors in animals. However, in rats contin-
uously exposed to diethylnitrosamine, 04_
ethylthymine accumulated in hepatocyte
DNA, whereas 06-ethylguanine levels
declined to nondetectable levels because of
the more efficient repair of06-ethylguanine
(34,35). Therefore, 04-ethylthymine may
be more important than 06-ethylguanine in
the induction ofhepatocellular tumors in
rats (34,35).
Once the procarcinogenic adduct is
identified, other issues remain: a) DNA
adducts may not be uniformly distributed
throughout thegenome (44); b) DNA repair
may be targeted to actively transcribed genes
(45) and to the transcribed strand (46); c)
mutational hot spots appear to play an
important role in carcinogenesis in humans
(47-49); d) cell replication, the rate of
which mayvary among different organs and
cell types (33,35), is required for mutagene-
sis to occur. Therefore, there might not be a
direct relationship between adduct levels in
bulk DNAand tumor response (33-37).
Third, iflowdoses oftoxic agents induce
apparently beneficial responses (e.g.,
enhanced longevity, lower incidence ofdis-
ease), how does and/or could the CPSC
address this? The FHSA only defines toxic
and hazardous. It does not define nontoxic
or nonhazardous and it does not address
beneficial effects. Therefore, beneficial effects
per se could not be addressed under the
FHSA: only the potential hazards could be
addressed. Any product that daimed a bene-
ficial effect could be under thejurisdiction of
otherfederal agencies.
There are at least two situations in
which a low dose of a toxic agent could
induce apparently beneficial effects. In one
situation the agent has no effect or a benefi-
cial effect at low levels and is toxic at higher
levels; that is, a threshold or a J-shaped
dose-response curve, respectively. Whereas
regulatory decisions under the FHSA are
risk based, the key issue is whether the expo-
sures that would occur during "reasonably
foreseeable handling and use" (19) would
present ahazard.
In the second situation a low-level
exposure at subtoxic doses could induce a
defense mechanism that protects against
a subsequent potentially toxic exposure;
the risk would depend on a prior expo-
sure at the lower dose. The pertinent issue
is whether the prior low-level exposure is
likely to occur during "reasonably foresee-
able handling and use" (19). One might
also consider whether the ability to induce
the appropriate defense mechanism is
universal or whether some individuals
might be deficient in the inducible defense
mechanism and thus be more susceptible.
Conclusions
The CPSC chronic hazard guidelines were
issued in 1992 (20). Theywere not intended
to be applied mechanically. Rather, the
guidelines are sufficiently flexible to allow
professional judgment and the latest science
to be incorporated into the risk-assessment
process. The default assumptions are meant
to be used only in the absence ofevidence to
the contrary. Alternative methods may be
substituted for the default assumptions on a
case-by-case basis, provided that theyare sup-
ported by appropriate data and are scientifi-
cally defensible. However, CPSC staff
considers that some changes from the default
procedures could have a profound effect on
the outcome ofa risk assessment. For exam-
ple, substituting a threshold-distribution
model for the multistage model in cancer risk
assessment could reduce the risk estimate by
orders ofmagnitude. Such a change should
be made only when there is a considerable
body ofevidence to support it and a degree
ofscientific consensus exists. The nongeno-
toxic carcinogen 2,3,7,8-tetrachlorodibenzo-
p-dioxin (TCDD) appears to act through a
receptor-mediated mechanism (50,51). An
early step in TCDD-induced carcinogenesis
is believed to be binding to thearyl hydrocar-
bon receptor, whichleads to alterations in the
expression ofcertain genes. Extensive study
ofthe effects ofTCDD on gene expression
suggests that receptor-mediated mechanisms
may result in either linear or nonlinear
responses at low doses (52,53). Therefore,
the knowledge that a certain carcinogen is
nongenotoxic or acts through a receptor is in
itselfinsufficient to abandon the default pro-
cedure forhigh-to-lowdoseextrapolation.
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